in the absence of a submission from the holder of the marketing authorisation.
temsirolimus (Torisel®) is not recommended for use within NHS Scotland.
Licensed indication under review: the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma [MCL].
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice45KB (PDF)
- Medicine name:
- temsirolimus (Torisel)
- SMC ID:
- Relapsed and/or refractory mantle cell lymphoma
- Pharmaceutical company
- Wyeth Pharmaceuticals
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 12 April 2010